



Pharmaceutical Committee

Update on the European Commission Expert Group on Safe and Timely Access to Medicines for Patients (STAMP)

27 March 2017



European
Commission

STAMP – 2014 - 2015

- **Early access initiatives**
conditional marketing authorisation, adaptive pathways and PRIority MEdicines (PRIME)
- **Compassionate use**
- **Repurposing of established medicines**
- **Off-label use** of medicinal products
- **Council conclusions**
- Synergies with **Health Technology Assessment** Network



European
Commission

STAMP meeting 13 – 14 March 2017

- **Repurposing** of established medicines – brainstorming
- **Off-label use** of medicinal products
- Proposal for *ad hoc* **synergy group** between regulatory and HTA bodies
- Updates on **early access initiatives** – adaptive pathways
- EMA report on 10 years of experience of **conditional marketing authorisation**
- Update on **policies for effective, accessible and resilient health systems**

Ad-hoc Synergy Group

- Equal numbers of HTA representatives (i.e. HTA Network and EUnetHTA JA3) and regulators (i.e. STAMP, HMA, EMA)
- **Objectives:**
 - To map the actions identified in the Reflection paper (on-going or planned by different fora), in order to create synergies and avoid duplication and uncertainty
 - To facilitate contacts/interactions between different fora to contribute to the common objective of facilitating access to medicines
 - To suggest the best way forward in specific areas identified in the Reflection Paper



European
Commission

Thank you for your attention

More information:

**[http://ec.europa.eu/health/documents/pharmaceutical-
committee/stamp/index_en.htm](http://ec.europa.eu/health/documents/pharmaceutical-committee/stamp/index_en.htm)**